Liposomal drug formulations for treatment of hematological malignancies
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Liposomal drug formulations for treatment of hematological malignancies
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-4
Publisher
Informa UK Limited
Online
2023-10-12
DOI
10.1080/14656566.2023.2269086
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia
- (2023) Han Yao et al. Cancer Medicine
- Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia
- (2022) Jan Philipp Bewersdorf et al. BLOOD
- R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group
- (2021) Juan‐Manuel Sancho et al. Cancer Medicine
- Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia
- (2021) Lydia L. Benitez et al. LEUKEMIA & LYMPHOMA
- Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML
- (2021) Jorge E. Cortes et al. Journal of Hematology & Oncology
- Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer
- (2020) Khojasteh Ghasemi et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
- (2019) Mark A. Schroeder et al. CLINICAL CANCER RESEARCH
- Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance
- (2019) Mariann Gyöngyösi et al. CARDIOVASCULAR RESEARCH
- A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia
- (2019) Benjamin K. Tomlinson et al. AMERICAN JOURNAL OF HEMATOLOGY
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma
- (2016) Robert Z. Orlowski et al. CANCER
- Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma
- (2016) Michael A. Fridrik et al. EUROPEAN JOURNAL OF CANCER
- Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin
- (2016) Grant H. Petersen et al. JOURNAL OF CONTROLLED RELEASE
- A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma
- (2016) P S Becker et al. Blood Cancer Journal
- Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
- (2013) Rachid C. Baz et al. AMERICAN JOURNAL OF HEMATOLOGY
- High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia
- (2012) Susan O'Brien et al. JOURNAL OF CLINICAL ONCOLOGY
- A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients
- (2011) Taimur Sher et al. BRITISH JOURNAL OF HAEMATOLOGY
- Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells
- (2011) Hyun Pyo Kim et al. EXPERIMENTAL HEMATOLOGY
- Liposomal daunorubicinversusstandard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia
- (2008) Roberto Latagliata et al. BRITISH JOURNAL OF HAEMATOLOGY
- In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy
- (2008) Paul Tardi et al. LEUKEMIA RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started